WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='18.206.194.21'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

Bright Minds Biosciences Inc. DRUG.CN / DRUG - Pot Stocks Charts, Financials, Analysts Price Targets, Insiders Transactions


Bright Minds Biosciences Inc.

CNSX: DRUG


Canadian symbol: DRUG.CN
US symbol: DRUG

Currency in CAD

Valuation Measures4

Market Cap (intraday) 8.86M
Enterprise Value 825.18k
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.15
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.10

Trading Information

Stock Price History

Beta (5Y Monthly) 1.66
52-Week Change 3-73.89%
S&P500 52-Week Change 318.47%
52 Week High 310.2000
52 Week Low 32.1000
50-Day Moving Average 33.7462
200-Day Moving Average 34.1413

Share Statistics

Avg Vol (3 month) 32.46k
Avg Vol (10 day) 31.2k
Shares Outstanding 53.77M
Implied Shares Outstanding 63.77M
Float 83.18M
% Held by Insiders 123.67%
% Held by Institutions 13.01%
Shares Short (Aug 14, 2023) 4218
Short Ratio (Aug 14, 2023) 40.04
Short % of Float (Aug 14, 2023) 40.01%
Short % of Shares Outstanding (Aug 14, 2023) 40.01%
Shares Short (prior month Jun 29, 2023) 4470

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:5
Last Split Date 3Jul 13, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Sept 29, 2022
Most Recent Quarter (mrq)Jun 29, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-62.37%
Return on Equity (ttm)-108.98%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-8.81M
Diluted EPS (ttm)-2.7600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.13M
Total Cash Per Share (mrq)2.15
Total Debt (mrq)91.41k
Total Debt/Equity (mrq)1.18%
Current Ratio (mrq)11.62
Book Value Per Share (mrq)2.05

Cash Flow Statement

Operating Cash Flow (ttm)-7.96M
Levered Free Cash Flow (ttm)-4.36M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen



Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10



Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.


Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363




Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, bool given in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 460
Company News Date

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710


Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesDRUG.CNIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711


Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Currency in CAD
Breakdown
23.67%% of Shares Held by All Insider
3.01%% of Shares Held by Institutions
3.94%% of Float Held by Institutions
9Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
AdvisorShares Investments, LLC103,063Jun 29, 20232.73%242,198
Two Sigma Securities, LLC3,345Jun 29, 20230.09%7,860
Checchi Capital Advisers, LLC2,828Jun 29, 20230.07%6,645
Blackrock Inc.2,360Jun 29, 20230.06%5,545
Renaissance Technologies, LLC2,240Jun 29, 20230.06%5,263
UBS Group AG420Jun 29, 20230.01%986
Royal Bank of Canada483Jun 29, 20230.01%1,135
Toronto Dominion Bank4Jun 29, 20230.00%9

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
AdvisorShares Trust-AdvisorShares Psychedelics ETF112,377Aug 30, 20232.98%264,085
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Bright Minds Biosciences Inc.


Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study-- Pro... Read More...

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending do... Read More...

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Bright Minds Biosciences-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B ---- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds --VANC... Read More...

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

<!-- Name:DistributionId Value:8804303 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1215554 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:5a4f8d74-a5c7-45ff-825b-146eb8df4874 --> — Presentation... Read More...

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Bright Minds Biosciences-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia ---- Company has transitioned from a discovery to a development organization –-- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 --VANCOUVER, British Columbi... Read More...

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

<!-- Name:DistributionId Value:8745619 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1215554 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:15d9ac77-e32d-4c3e-8cc8-486c808a7e18 --> VANCOUVER, Bri... Read More...

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce tha... Read More...

Bright Minds Biosciences Announces Non-Brokered Private Placement

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a n... Read More...

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology com... Read More...

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

VANCOUVER, British Columbia, Aug. 31, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I... Read More...

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in... Read More...

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 --  Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment o... Read More...

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted t... Read More...

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Bright Minds BiosciencesVANCOUVER, British Columbia, March 14, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the successful completi... Read More...

Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference

VANCOUVER, British Columbia, March 08, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Company management will present virtually ... Read More...

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

VANCOUVER, British Columbia, Jan. 04, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and ... Read More...

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

VANCOUVER, British Columbia, Dec. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will... Read More...

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on... Read More...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

VANCOUVER, British Columbia, Nov. 03, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the lis... Read More...

Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference

VANCOUVER, British Columbia, Oct. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright ... Read More...

Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance

VANCOUVER, British Columbia, Sept. 08, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. ... Read More...

Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

Additions of industry veterans, Dr. Emer Leahy to the Board of Directors and Dr. Tom Lategan as Vice President of Regulatory Affairs, position the Company to advance drug development programsVANCOUVER, British Columbia, June 14, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechno... Read More...
Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5004,320.060.23%Negative
Euro STOXX 504,207.160.13%Negative
FTSE 1007,683.910.07%Positive
Nikkei 22532,402.410.52%Negative

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5004,320.060.23%Negative
Euro STOXX 504,207.160.13%Negative
FTSE 1007,683.910.07%Positive
Nikkei 22532,402.410.52%Negative


Share this page